{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Morita D"],"funding":["Naito Foundation","Adopt-A-Scientist Funding","International Medical Research Foundation","National Heart, Lung, and Blood Institute","NHLBI NIH HHS","National Cancer Institute","NCI NIH HHS"],"pagination":["e009741"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11629014"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["<h4>Background</h4>Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested \"Armed\" OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolytic/helper-dependent adenovirus system (CAdVEC), in which tumors are coinfected with an OAd and a non-replicating helper-dependent Ad (HDAd). We recently demonstrated that a single low-dose CAdVEC expressing interleukin-12, programmed death-ligand 1 blocker, and HSV thymidine kinase safety switch (CAdTrio) induces significant antitumor effects in patients, including complete response. Similar to previous OAd studies, all patients primarily amplified Ad-specific T cells after treatment how"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity."],"pmcid":["PMC11629014"],"funding_grant_id":["N/A","P30-CA125123","P50 CA186784","T32HL092332","P50-CA186784-07","T32 HL092332","P30 CA125123"],"pubmed_authors":["Woods M","Lim B","Rosewell Shaw A","Suzuki M","Biegert G","Porter C","Morita D","Vasileiou S"],"additional_accession":[]},"is_claimable":false,"name":"Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.","description":"<h4>Background</h4>Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested \"Armed\" OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolytic/helper-dependent adenovirus system (CAdVEC), in which tumors are coinfected with an OAd and a non-replicating helper-dependent Ad (HDAd). We recently demonstrated that a single low-dose CAdVEC expressing interleukin-12, programmed death-ligand 1 blocker, and HSV thymidine kinase safety switch (CAdTrio) induces significant antitumor effects in patients, including complete response. Similar to previous OAd studies, all patients primarily amplified Ad-specific T cells after treatment how","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-07-15T08:03:18.004Z","creation":"2025-04-19T14:37:21.656Z"},"accession":"S-EPMC11629014","cross_references":{"pubmed":["39653552"],"doi":["10.1136/jitc-2024-009741"]}}